Walleye Capital LLC Acquires Shares of 347,898 Tyra Biosciences, Inc. $TYRA

Walleye Capital LLC acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 347,898 shares of the company’s stock, valued at approximately $11,112,000. Walleye Capital LLC owned approximately 0.58% of Tyra Biosciences as of its most recent SEC filing.

Other institutional investors also recently modified their holdings of the company. Commodore Capital LP lifted its holdings in shares of Tyra Biosciences by 226.3% in the 2nd quarter. Commodore Capital LP now owns 3,100,000 shares of the company’s stock worth $29,667,000 after purchasing an additional 2,150,000 shares in the last quarter. Janus Henderson Group PLC increased its stake in Tyra Biosciences by 32.5% during the 1st quarter. Janus Henderson Group PLC now owns 3,890,589 shares of the company’s stock valued at $148,867,000 after purchasing an additional 955,147 shares in the last quarter. Farallon Capital Management LLC increased its stake in Tyra Biosciences by 80.7% during the 4th quarter. Farallon Capital Management LLC now owns 2,066,818 shares of the company’s stock valued at $54,337,000 after purchasing an additional 923,000 shares in the last quarter. Jennison Associates LLC acquired a new position in Tyra Biosciences during the first quarter worth $24,222,000. Finally, Caligan Partners LP raised its holdings in Tyra Biosciences by 266.8% during the third quarter. Caligan Partners LP now owns 696,825 shares of the company’s stock worth $9,749,000 after buying an additional 506,875 shares during the last quarter. 84.14% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. JonesTrading started coverage on shares of Tyra Biosciences in a report on Wednesday, June 17th. They set a “buy” rating and a $56.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of Tyra Biosciences in a report on Friday, July 17th. Wolfe Research started coverage on shares of Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $45.00 price target on shares of Tyra Biosciences in a research report on Thursday, May 14th. Finally, Jefferies Financial Group reiterated a “buy” rating and set a $42.00 price target on shares of Tyra Biosciences in a research note on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, Tyra Biosciences has a consensus rating of “Moderate Buy” and a consensus target price of $46.90.

Tyra Biosciences Trading Up 1.1%

Shares of NASDAQ:TYRA opened at $25.29 on Friday. The stock’s fifty day simple moving average is $29.75 and its two-hundred day simple moving average is $32.50. Tyra Biosciences, Inc. has a 1-year low of $9.96 and a 1-year high of $40.65. The stock has a market cap of $1.51 billion, a PE ratio of -10.54 and a beta of 0.77.

Tyra Biosciences (NASDAQ:TYRA) last posted its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, sell-side analysts forecast that Tyra Biosciences, Inc. will post -2.74 earnings per share for the current fiscal year.

Tyra Biosciences Company Profile

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.